Barclays
CMPX icon

Barclays’s Compass Therapeutics CMPX Stock Holding History

Barclays’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.18M Buy
790,041
+195,265
+33% +$1.13M ﹤0.01% 1929
2025
Q4 		$3.19M Buy
594,776
+372,358
+167% +$1.72M ﹤0.01% 2590
2025
Q3 		$778K Sell
222,418
-19,303
-8% -$61K ﹤0.01% 3523
2025
Q2 		$628K Buy
241,721
+122,990
+104% +$254K ﹤0.01% 3631
2025
Q1 		$226K Sell
118,731
-74,035
-38% -$197K ﹤0.01% 3979
2024
Q4 		$280K Buy
192,766
+22,521
+13% +$37.4K ﹤0.01% 4147
2024
Q3 		$313K Buy
170,245
+112,614
+195% +$140K ﹤0.01% 4055
2024
Q2 		$57.6K Sell
57,631
-18,282
-24% -$26.7K ﹤0.01% 4151
2024
Q1 		$150K Sell
75,913
-49,573
-40% -$85.7K ﹤0.01% 4259
2023
Q4 		$196K Buy
125,486
+95,183
+314% +$165K ﹤0.01% 4428
2023
Q3 		$59.7K Sell
30,303
-1,618
-5% -$4K ﹤0.01% 3797
2023
Q2 		$102K Sell
31,921
-9,065
-22% -$28.5K ﹤0.01% 3557
2023
Q1 		$134K Buy
40,986
+22,761
+125% +$89.4K ﹤0.01% 4021
2022
Q4 		$91.7K Buy
18,225
+17,851
+4,773% +$71.2K ﹤0.01% 4276
2022
Q3 		$1K Buy
+374
New +$1.03K ﹤0.01% 4680

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Barclays's CMPX Position: Q1 2026 in Review

Barclays increased its Compass Therapeutics (CMPX) stake by 33% in Q1 2026, buying an estimated $1.13M and bringing the position to 790,041 shares worth $4.18M. The position accounts for ﹤0.01% of the portfolio, ranked #1929.

Barclays first reported a position in CMPX in Q3 2022 and has held it in 15 quarters since. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Barclays held 790,041 shares of Compass Therapeutics worth $4.18M as of Q1 2026.
  • Barclays bought 195,265 Compass Therapeutics shares in Q1 2026, an estimated $1.13M.
  • Compass Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1929 holding.
  • Barclays first reported a position in Compass Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.